Magnetic Resonance Spectroscopy in Alzheimer's Disease

Magnetic resonance spectroscopy (MRS) is a non-invasive imaging modality that permits the quantification of cerebral metabolites in vivo. In the context of Alzheimer’s disease (AD), MRS has been employed to interrogate neurometabolic alterations within key regions of the brain, including the hippocampus, posterior cingulate cortex and frontal lobes. Proton (1H) MRS and phosphorus (31P) MRS are the principal variants used to measure concentrations of markers such as N-acetylaspartate, myo-inositol, creatine and phosphocreatine. Changes in these metabolites reflect neuronal integrity, glial activation, cellular energy reserves and membrane turnover. The ability of MRS to detect early disruptions in brain biochemistry underpins its value both as a research tool for elucidating disease mechanisms and as a candidate biomarker for diagnosis, prognostication and monitoring of therapeutic interventions. Recent technical advances, including high-field scanners, whole-brain spectroscopic imaging and integration with positron emission tomography, have enhanced spatial resolution and metabolic specificity. These developments promise to refine our understanding of AD pathophysiology, facilitate multi-modal approaches and support the translation of MRS into clinical practice on a global scale.

Research from Nature Portfolio

Recent studies have exploited MRS to delineate the bioenergetic and inflammatory signatures of Alzheimer’s pathology. In one investigation, high-field 31P-MRS revealed sex- and menopause-dependent variations in brain phosphorus metabolites among cognitively normal midlife adults at risk for Alzheimer’s disease. This work demonstrated that women, particularly during perimenopause and post-menopause, exhibit elevated adenosine triphosphate utilisation in frontal and temporoparietal regions, suggesting a dynamic adaptation of neuronal energy metabolism in relation to endocrine ageing. In a separate experimental model, proton MRS was applied longitudinally to a transgenic mouse bearing amyloid pathology to compare microglial activation responses with healthy controls. The study identified distinct spectroscopic markers of lipid and macromolecule levels following immune stimulation, and highlighted the limitations of myo-inositol as a universal glial indicator in the presence of amyloid-β accumulation. Together, these findings underscore MRS as a versatile tool for probing both cellular energetics and neuroinflammation in Alzheimer’s disease.

Magnetic Resonance Spectroscopy in Alzheimer's Disease publication trend

The graph below shows the total number of articles in magnetic resonance spectroscopy in alzheimer's disease across all publications each year (not limited to Nature Index journals).

Technical terms

Proton magnetic resonance spectroscopy (1H-MRS): A non-invasive imaging method that quantifies hydrogen-containing neurometabolites in vivo.

Phosphorus magnetic resonance spectroscopy (31P-MRS): A technique to measure phosphorus-containing compounds involved in cellular energy metabolism.

N-acetylaspartate (NAA): A marker of neuronal density and viability, typically reduced in neurodegenerative conditions.

Myo-inositol (mI): A glial marker that increases with astrocytic proliferation and neuroinflammation.

Creatine (Cr) and phosphocreatine (PCr): Components of cellular energy buffering systems used to infer brain energy status.

Amyloid-β (Aβ): A peptide that accumulates in plaques and is a hallmark of Alzheimer’s disease pathology.

References

1. Neurometabolic topography and associations with cognition in Alzheimer's disease: A whole‐brain high‐resolution 3D MRSI study. Alzheimer's & Dementia (2024).
2. Magnetic Resonance Spectroscopy discriminates the response to microglial stimulation of wild type and Alzheimer’s disease models. Scientific Reports (2016).
3. Meta-Analysis of Neurochemical Changes Estimated via Magnetic Resonance Spectroscopy in Mild Cognitive Impairment and Alzheimer's Disease. Frontiers in Aging Neuroscience (2021).
4. Sex and menopause impact 31P-Magnetic Resonance Spectroscopy brain mitochondrial function in association with 11C-PiB PET amyloid-beta load. Scientific Reports (2022).